活检针道注射血凝酶可减少CT引导经皮胸肺活检后的主要并发症
回顾性研究纳入100例拟行CT引导经皮胸肺活检的未确诊肺部病变患者,比较活检针道注射血凝酶(0.2-0.5单位)与不注射的并发症。血凝酶组气胸和肺出血发生率分别为8%和6%,显著低于非血凝酶组的22%和20%(p=0.04和0.03);咯血两组无显著差异。结论认为针道注射血凝酶可降低术后气胸和肺出血发生率。
要点
- 血凝酶组气胸发生率8%,非血凝酶组22%,差异有统计学意义(p=0.04)。
- 血凝酶组肺出血发生率6%,非血凝酶组20%,差异有统计学意义(p=0.03)。
- 咯血发生率血凝酶组6% vs 非血凝酶组2%,无统计学显著差异(p=0.23)。
核心结论
- 活检针道注射血凝酶降低了经皮胸肺活检术后气胸和肺出血的发生率。
研究设计与样本
- 回顾性研究,纳入2020年1月至2021年3月拟行经皮胸肺活检的未确诊肺部病变患者100例(男44例,平均年龄53岁),使用17 G同轴系统行CT引导活检,按是否接受针道血凝酶注射(0.2-0.5单位)分为血凝酶组和非血凝酶组。
诊断标准与关键数值
- 总体气胸发生率为15%,肺出血发生率为13%。
- 气胸发生率血凝酶组8% vs 非血凝酶组22%(p=0.04)。
- 肺出血发生率血凝酶组6% vs 非血凝酶组20%(p=0.03)。
- 咯血发生率血凝酶组6% vs 非血凝酶组2%(p=0.23),无统计学显著差异。
临床应用与阅片要点
- 原文结论认为活检针道注射血凝酶可减少经皮胸肺活检术后气胸和肺出血。
- 气胸和肺出血与患者体位、病变位置或病理结果均无统计学显著关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To determine whether the injection of haemocoagulase into the biopsy tract can reduce pneumothorax and pulmonary haemorrhage after computed tomography (CT)-guided percutaneous transthoracic lung biopsy (PTLB).
MATERIALS AND METHODS: A retrospective study was performed involving patients with undiagnosed pulmonary lesions scheduled for PTLB between January 2020 and March 2021. Patients were assigned to the haemocoagulase group or the non-haemocoagulase group. After CT-guided biopsies were performed with a 17 G coaxial system, patients in the haemocoagulase group received a haemocoagulase injection (0.2-0.5 units) in the biopsy tract as the sheath was withdrawn. Postoperative image studies were performed to evaluate complications, including pneumothorax and pulmonary haemorrhage. Factors, including the patient's position, lesion location, and pathological results, were evaluated to determine their associations with the complications.
RESULTS: A total of 100 patients were included, with 44 men and a mean age of 53 years old. The overall incidences of pneumothorax and pulmonary haemorrhage were 15% and 13%, respectively. The incidences of pneumothorax and pulmonary haemorrhage were statistically significantly lower in the haemocoagulase group (8% and 6%, respectively) than in the non-haemocoagulase group (22% and 20%, respectively; p=0.04 and 0.03, respectively). There was no statistically significant difference in haemoptysis between the haemocoagulase (6%) and non-haemocoagulase (2%) groups (p=0.23). There were also no statistically significant associations of pneumothorax or pulmonary haemorrhage with the patients' positions, lesion location, or pathological results.
CONCLUSION: Biopsy tract haemocoagulase injection reduced the incidences of postoperative pneumothorax and pulmonary haemorrhage after PTLB.
引用
- Zhou, Luo, Gu, et al. Biopsy-tract haemocoagulase injection reduces major complications after CT-guided percutaneous transthoracic lung biopsy. Clin Radiol. 2022. PMID: 35788268. doi:10.1016/j.crad.2022.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。